TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Discovery and clinical development at TIDES Europe 2026

Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website

32 organizations at TIDES Europe 2026 present work in discovery & clinical: 25 drug developers, 4 suppliers and service providers and 3 academic, government and non-profit bodies. Between them they bring 51 presentations to the program. Most represented: Novo Nordisk (6 on the program), Eli Lilly and Company (4 on the program), AstraZeneca (4 on the program). As of Nov 2, 2026.

All 167 organizations at TIDES Europe 2026 →

Format
Top represented
Showing 1–12 of 32 organizations
OrganizationTIDES Europe 2026 Attendance
Novo Nordisk
Bagsværd, Denmark
Large pharma
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide.
Keynote
Tue Nov 3
13:50–14:25
Next Generation GLP-1 Therapeutics
How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills.
PeptidesObesity & Metabolic
Talk
Wed Nov 4
08:05–08:35
Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides
Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align.
with Roche
Talk
Thu Nov 5
09:05–09:35
Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme
Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect.
Talk
Thu Nov 5
08:35–09:05
siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism
How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out.
Talk
Fri Nov 6
09:10–10:00
Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape
What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for.
Post-event symposium · with Cantoni Therapeutics, Aphaia Pharma, Constructive Bio
Talk
Fri Nov 6
08:40–09:10
Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To
Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching.
Post-event symposium
Talk
Fri Nov 6
11:40–12:05
Presentation: Energy Expenditure Modulation as an Emerging Therapeutic Strategy for Obesity
Post-event symposium: Clinical & Translational Updates
Eli Lilly and Company
Indianapolis, IN
Large pharma
Global pharmaceutical company whose peptide medicines include tirzepatide, with programs in oligonucleotide therapeutics.
Keynote
Tue Nov 3
13:15–13:50
Making Oligonucleotides a High-Volume Reality: Next-Gen Platforms and Strategy for Oligonucleotide Manufacturing
Keynote Sessions - MAIN CONFERENCE
OligonucleotidesCMC & Manufacturing
Keynote
Tue Nov 3
14:25–15:00
Retatrutide: From Breakthrough Science to Global Medicine — The CMC Story Behind a Novel GIP, GLP-1, and Glucagon Receptor Agonist
How the obesity and diabetes drug retatrutide is made at world supply scale by joining peptide fragments in solution with far less waste.
PeptidesCMC & Manufacturing
Talk
Wed Nov 4
16:45–17:15
Made to Scale: What Tirzepatide's Manufacturing Challenge Teaches Us About Innovation Under Pressure
Lessons from scaling up production of the diabetes and obesity drug tirzepatide, from an odd result at the bench to tonnes of material.
Chair
Thu Nov 5
08:00–08:05
Chairpersons Remarks: Targeted Delivery of Oligonucleotides
Oligonucleotide Discovery, Preclinical and Clinical
Talk
Thu Nov 5
16:00–16:30
Cycle Time Is a Quality Metric: Eloralintide from Discovery to Clinical Proof of Concept
How the peptide eloralintide moved from discovery into patients by overlapping chemistry and biology cycles instead of running them one after another.
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global pharmaceutical company developing medicines across modalities, including oligonucleotide and peptide therapeutics.
Talk
Thu Nov 5
15:00–15:30
Maintaining Diastereomeric Control in Phosphorothioate siRNAs: Integrated Analytical and Manufacturing Approaches for Reliable Clinical Development
Why purifying siRNA can quietly shift the mix of mirror-image sulfur linkages between batches, and how to keep that mix steady.
Talk
Thu Nov 5
09:05–09:35
Peptide-Targeted Delivery of Oligonucleotide Therapeutics
Early, pre-clinical work on a short peptide that steers gene-silencing drugs into the tissue where they are meant to act.
Talk
Thu Nov 5
09:05–09:35
Rethinking Green Credentials for Oligo Manufacturing
Why simple waste-per-kilogram scores misjudge how green oligonucleotide production is, and what real improvement would involve.
Talk
Thu Nov 5
08:35–09:05
Systematic Route Design for Fragment-Based Peptide Synthesis: Enabling Liquid-Phase Transition
A way to choose where to split a long peptide into fragments so it can be built in solution with better yield.
Biotech
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases.
Talk
Thu Nov 5
15:00–15:30
Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline
Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them.
Talk
Thu Nov 5
10:45–11:25
Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing
Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies.
with Almac
European Medicines Agency
Amsterdam, Netherlands
Gov/NGO
European Union agency that evaluates and supervises medicines, including oligonucleotide and peptide products.
Talk
Wed Nov 4
15:00–15:30
EMA Perspectives on mRNA Vaccines and Therapeutics
Where European regulators stand on quality rules for mRNA vaccines and medicines, and which problems keep coming up in applications.
Talk
Wed Nov 4
09:05–09:35
Regulatory Landscape for Synthetic Peptides and Oligonucleotides: EMA Insights and Guideline Updates
An update on two draft European guidelines for synthetic peptides and oligonucleotides, the feedback they drew and the problems seen in filings.
Wave Life Sciences
Cambridge, Massachusetts
Biotech
Develops stereopure oligonucleotide medicines, including siRNA, antisense and RNA editing candidates.
Talk
Wed Nov 4
09:05–09:35
Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA
Designing siRNA the way chemists design small-molecule drugs, controlling each linkage to get lasting gene silencing in mouse liver and kidney.
Talk
Thu Nov 5
16:30–17:00
Synthesis and Characterization of Stereopure Chimeric Oligonucleotides
Making and testing oligonucleotides in which every backbone link has one fixed mirror-image form, in small batches, to link structure to activity.
Consulting & services
Consultancy working on oligonucleotide chemistry, manufacturing and controls from the early discovery stage onward.
Talk
Tue Nov 3
09:10–09:45
Drug Substance and Drug Product and How CMC Early in the Discovery Lifecycle Can Help
Why a careful handover from making the drug substance to making the finished product makes the paperwork for first clinical trials easier.
Chair
Thu Nov 5
13:55–14:00
Chairman's Remarks: Oligonucleotide Preclinical and Clinical Updates
Oligonucleotide Discovery, Preclinical and Clinical · with Sheba Medical Center
NT
noctuRNA Therapeutics
Barcelona, Spain
Biotech
Pompeu Fabra University spin-off developing circular RNA therapeutics for infectious, neuromuscular and neurodegenerative diseases.
Chair
Wed Nov 4
13:55–14:00
Chairman’s Remarks: Emerging RNA and OIigonucleotide Modalities
Oligonucleotide Discovery, Preclinical and Clinical
Talk
Wed Nov 4
16:45–17:15
Novel Circular RNA Therapeutics for Infectious and Non-infectious Diseases
Engineered circular RNA that grabs onto folded, disease-causing RNA, tested in amyotrophic lateral sclerosis, myotonic dystrophy and viral infection.
SM
Sheba Medical Center
Ramat Gan, Israel
Academic
Israeli teaching hospital in Ramat Gan whose N=1 program makes individually tailored antisense drugs for patients with rare diseases.
Chair
Thu Nov 5
13:55–14:00
Chairman's Remarks: Oligonucleotide Preclinical and Clinical Updates
Oligonucleotide Discovery, Preclinical and Clinical · with ML Consult
Talk
Thu Nov 5
17:00–17:30
Overcoming the Cost Bottleneck in N=1 Therapeutics: A Highly Affordable, GMP-Compliant CMC Platform for Rapid Clinical Deployment
A cheaper, standardised way to make a one-patient antisense drug under regulated manufacturing rules, used for a child with a rare brain disorder.
Silence Therapeutics
London, United Kingdom
Biotech
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases.
Talk
Wed Nov 4
10:15–10:45
Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited
A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages.
Talk
Fri Nov 6
11:15–11:40
Presentation: Genetically-Validated INHBE Silencing with SLN098 siRNA for Enhanced Fat Loss and Lean Mass Preservation
Post-event symposium: Clinical & Translational Updates
Analytics & instrumentsSilver sponsor
Spatial biology tools built on RNAscope in situ hybridization and the COMET system: reagents, instruments and software for RNA and protein detection.
Booth
Exhibiting at Booth K8
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Wed Nov 4
12:50–13:10
Spatially Resolving RNA Therapeutics in Heterogenous Organs: RNAscope to Correlate Biodistribution and Efficacy at Single-Cell Resolution
How a tissue staining method shows which individual cells take up an RNA drug and whether it changes gene activity there.
OligonucleotidesDiscovery & Clinical
Catalent
Somerset, NJ
CDMO & CROBronze sponsor
Contract development and manufacturing organization for drug products, including oral delivery technologies and injectable formulation and fill-finish.
Booth
Exhibiting (no floor booth listed)
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Wed Nov 4
12:30–12:50
Advancing Beyond Injections: Technologies Driving Oral Delivery of Peptides
Ways to get peptide drugs absorbed when swallowed rather than injected, using fatty carriers, slow-release capsules and the lining of the mouth.
PeptidesDiscovery & Clinical

Explore the full TIDES Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Amsterdam. Leave your work email and we’ll be in touch.

Privacy

Download the full TIDES Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in discovery & clinical

Tell us what you sell and we’ll find the people at organizations working on discovery & clinical most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse TIDES Europe 2026 by

Exhibit hall

Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction